Prognostic Value of Inflammation-Immunity-Nutrition Score and Inflammatory Burden Index for Hepatocellular Carcinoma Patients After Hepatectomy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Live. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235(3):373–382. doi:10.1097/00000658-200203000-00009
   PubMed Web of Science ®Google Scholar
• Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol. 2018;2(1):6. doi:10.1038/s41698-018-0048-z
   PubMed Web of Science ®Google Scholar
• van Dijk AM, Coppens BJP, van Beers MA, et al. Nutritional status in patients with hepatocellular carcinoma: potential relevance for clinical outcome. Eur J Intern Med. 2022;104:80–88. doi:10.1016/j.ejim.2022.07.002
   PubMed Web of Science ®Google Scholar
• Qian W, Xiao-Jian J, Jun H, Liang L, Xiao-Yong C. Comparison of the value of multiple preoperative objective nutritional indices for the evaluation of prognosis after hepatectomy for hepatocellular carcinoma. Nutr Cancer. 2022;74:1–11.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen D, Jin L, Xu C, Zhao W, Hu W. Prognostic significance of neutrophil-to-lymphocyte ratio and C-Reactive protein/albumin ratio in luminal breast cancers with HER2-negativity. Front Oncol. 2022;12:845935. doi:10.3389/fonc.2022.845935
   PubMed Web of Science ®Google Scholar
• Ni HH, Lu Z, Huang X, et al. Combining pre- and postoperative lymphocyte-C-reactive protein ratios can better predict hepatocellular carcinoma prognosis after partial hepatectomy. J Inflamm Res. 2022;15:2229–2241. doi:10.2147/JIR.S359498
   PubMed Web of Science ®Google Scholar
• Feng J, Wang L, Yang X, Chen Q. Development and validation of a novel pre-operative comprehensive prognostic score in esophageal squamous cell carcinoma. Bosn J Basic Med Sci. 2022;22(3):460–470. doi:10.17305/bjbms.2021.6350
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang Q, Ge Y, et al. Prognostic roles of inflammation- and nutrition-based indicators for female patients with cancer. J Inflamm Res. 2022;15:3573–3586. doi:10.2147/JIR.S361300
   PubMed Web of Science ®Google Scholar
• Mei J, Sun XQ, Lin WP, et al. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after anti-PD-1 therapy. J Inflamm Res. 2021;14:3879–3890. doi:10.2147/JIR.S325600
   PubMed Web of Science ®Google Scholar
• Li XY, Yao S, He YT, et al. Inflammation-immunity-nutrition score: a novel prognostic score for patients with resectable colorectal cancer. J Inflamm Res. 2021;14:4577–4588. doi:10.2147/JIR.S322260
   PubMed Web of Science ®Google Scholar
• Jiang P, Wang J, Gong C, Yi Q, Zhu M, Hu Z. A nomogram model for predicting recurrence of stage I-III Endometrial Cancer Based on Inflammation-Immunity-Nutrition Score (IINS) and traditional classical predictors. J Inflamm Res. 2022;15:3021–3037. doi:10.2147/JIR.S362166
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liang Y, Zhong D, et al. Prognostic value of inflammation-immunity-nutrition score in patients with hepatocellular carcinoma treated with anti-PD-1 therapy. J Clin Lab Anal. 2022;36(5):e24336. doi:10.1002/jcla.24336
   PubMed Web of Science ®Google Scholar
• Xie H, Ruan G, Ge Y, et al. Inflammatory burden as a prognostic biomarker for cancer. Clin Nutr. 2022;41(6):1236–1243. doi:10.1016/j.clnu.2022.04.019
   PubMed Web of Science ®Google Scholar
• Taniai T, Haruki K, Furukawa K, et al. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. Int J Clin Oncol. 2021;26(10):1922–1928. doi:10.1007/s10147-021-01964-2
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang K, Ni J, et al. Combination of C-reactive protein and neutrophil-to-lymphocyte ratio as a novel prognostic index in patients with bladder cancer after radical cystectomy. Front Oncol. 2021;11:762470. doi:10.3389/fonc.2021.762470
   PubMed Web of Science ®Google Scholar
• Sprinzl MF, Kirstein MM, Koch S, et al. Improved prediction of survival by a risk factor-integrating inflammatory score in sorafenib-treated hepatocellular carcinoma. Liver Cancer. 2019;8(5):387–402. doi:10.1159/000492628
   PubMed Web of Science ®Google Scholar
• Dolan RD, McSorley ST, Park JH, et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018;119(1):40–51. doi:10.1038/s41416-018-0095-9
   PubMed Web of Science ®Google Scholar
• Qi WX, Xiang Y, Zhao S, Chen J. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother. 2021;70(11):3199–3206. doi:10.1007/s00262-021-02926-3
   PubMed Web of Science ®Google Scholar
• Dupré A, Malik HZ. Inflammation and cancer: what a surgical oncologist should know. Eur J Surg Oncol. 2018;44(5):566–570. doi:10.1016/j.ejso.2018.02.209
   PubMed Web of Science ®Google Scholar
• Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–230. doi:10.1016/j.critrevonc.2013.03.010
   PubMed Web of Science ®Google Scholar
• Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. doi:10.1186/s12199-018-0740-1
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812. doi:10.1172/JCI200318921
   PubMed Web of Science ®Google Scholar
• Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61(9):824–833. doi:10.1136/jech.2006.051292
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008;123(5):1133–1140. doi:10.1002/ijc.23606
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Heinzel S, Marchingo JM, Horton MB, Hodgkin PD. The regulation of lymphocyte activation and proliferation. Curr Opin Immunol. 2018;51:32–38. doi:10.1016/j.coi.2018.01.002
   PubMed Web of Science ®Google Scholar
• Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg. 2012;147(4):366–372. doi:10.1001/archsurg.2012.35
   PubMed Web of Science ®Google Scholar
• Que H, Fu Q, Lan T, Tian X, Wei X. Tumor-associated neutrophils and neutrophil-targeted cancer therapies. Biochim Biophys Acta Rev Cancer. 2022;1877:188762. doi:10.1016/j.bbcan.2022.188762
   PubMed Web of Science ®Google Scholar
• Cristinziano L, Modestino L, Loffredo S, et al. Anaplastic thyroid cancer cells induce the release of mitochondrial extracellular DNA traps by viable neutrophils. J Immunol. 2020;204(5):1362–1372. doi:10.4049/jimmunol.1900543
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Masuda T, Yamaguchi K, et al. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. Int J Clin Oncol. 2020;25(1):74–81. doi:10.1007/s10147-019-01539-2
   PubMed Web of Science ®Google Scholar